The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Commercialization Patent License to practice the inventions embodied in the U.S. Patents and Patent Applications listed in the Supplementary Information section of this notice to NantBioScience, Inc., located in, California, USA.
Document
Prospective Grant of Exclusive Patent License: Development, Commercial Application and Use of Fulvestrant in Combination Therapy for the Treatment of Cancers
The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Commerciali...
Legal Citation
Federal Register Citation
Use this for formal legal and research references to the published document.
82 FR 32712
Web Citation
Suggested Web Citation
Use this when citing the archival web version of the document.
“Prospective Grant of Exclusive Patent License: Development, Commercial Application and Use of Fulvestrant in Combination Therapy for the Treatment of Cancers,” thefederalregister.org (July 17, 2017), https://thefederalregister.org/documents/2017-14860/prospective-grant-of-exclusive-patent-license-development-commercial-application-and-use-of-fulvestrant-in-combination-t.